Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial
暂无分享,去创建一个
W. Novotny | P. Marlton | A. Roberts | S. Opat | C. Tam | J. Burger | J. Seymour | J. Trotman | D. Simpson | D. Gottlieb | J. Muñoz | Jane E. Huang | K. Wu | G. Cull | S. Atwal